Biotech veterans John Maraganore and Clive Meanwell have launched Corsera Health, aiming to prevent cardiovascular disease through an AI-powered early risk assessment tool combined with a dual-acting RNAi therapeutic targeting PCSK9 and angiotensinogen. The startup secured $50 million in initial funding and plans to initiate clinical trials by year-end. Their AI platform, Klotho Health, is designed to identify high-risk individuals earlier for timely interventions. This venture exemplifies an emerging model focused on disease interception and precision therapeutics in cardiometabolic health.